In an effort to greater prepare HCPs and to avoid potential shortages, the company targets Q3 as the shipment date.

Ron Lanton, Partner, Lanton Law, weighs in on the potential international trade, pricing, and access implications of tying US drug costs to those in other developed countries under the Most Favored ...

In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceutical companies must move from traditional ...

A cross-sectional study explores how full-benefit dual-eligible beneficiaries differ across MA plans with differing levels of ...

In the second part of her Pharma Commerce video interview, Maggie McCullough, PolicyMap’s CEO, details what the company’s ...

A new observational study finds that people with diabetes taking GLP-1 drugs have a low but doubled risk of developing neovascular age-related macular degeneration, an eye disease that can cause ...

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ...

In the first part of her Pharma Commerce video interview, Maggie McCullough, PolicyMap’s CEO, explains how geospatial mapping ...

A Pharmaceutical Executive article explores how specialty pharmacy programs can significantly improve outcomes for patients with rare diseases—like cystic fibrosis—by providing faster access to ...